Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Intersect ENT

Nasdaq:XENT
Snowflake Description

Excellent balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XENT
Nasdaq
$307M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Intersect ENT has significant price volatility in the past 3 months.
XENT Share Price and Events
7 Day Returns
-9.5%
NasdaqGM:XENT
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-67%
NasdaqGM:XENT
-2%
US Pharmaceuticals
-10%
US Market
XENT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Intersect ENT (XENT) -9.5% -59.9% -61.7% -67% -41.2% -63.5%
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • XENT underperformed the Pharmaceuticals industry which returned -2% over the past year.
  • XENT underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
XENT
Industry
5yr Volatility vs Market

Value

 Is Intersect ENT undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Intersect ENT to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Intersect ENT.

NasdaqGM:XENT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:XENT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.63
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.629 (1 + (1- 21%) (3.97%))
0.764
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.8 * 5.44%)
6.09%

Discounted Cash Flow Calculation for NasdaqGM:XENT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Intersect ENT is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:XENT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.09%)
2020 -45.27 Analyst x3 -42.67
2021 -24.67 Analyst x3 -21.92
2022 -9.10 Analyst x3 -7.62
2023 -7.80 Analyst x1 -6.16
2024 3.40 Analyst x1 2.53
2025 5.23 Est @ 53.75% 3.67
2026 7.22 Est @ 38.15% 4.77
2027 9.19 Est @ 27.23% 5.72
2028 10.99 Est @ 19.58% 6.45
2029 12.55 Est @ 14.23% 6.95
Present value of next 10 years cash flows $-48.00
NasdaqGM:XENT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $12.55 × (1 + 1.74%) ÷ (6.09% – 1.74%)
$293.41
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $293.41 ÷ (1 + 6.09%)10
$162.42
NasdaqGM:XENT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-48.00 + $162.42
$114.42
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $114.42 / 32.30
$3.54
NasdaqGM:XENT Discount to Share Price
Calculation Result
Value per share (USD) From above. $3.54
Current discount Discount to share price of $9.52
= -1 x ($9.52 - $3.54) / $3.54
-168.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Intersect ENT is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Intersect ENT's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Intersect ENT's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:XENT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.37
NasdaqGM:XENT Share Price ** NasdaqGM (2020-04-07) in USD $9.52
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Intersect ENT.

NasdaqGM:XENT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:XENT Share Price ÷ EPS (both in USD)

= 9.52 ÷ -1.37

-6.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intersect ENT is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Intersect ENT is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Intersect ENT's expected growth come at a high price?
Raw Data
NasdaqGM:XENT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
7.5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Intersect ENT, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Intersect ENT's assets?
Raw Data
NasdaqGM:XENT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.66
NasdaqGM:XENT Share Price * NasdaqGM (2020-04-07) in USD $9.52
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:XENT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:XENT Share Price ÷ Book Value per Share (both in USD)

= 9.52 ÷ 3.66

2.6x

* Primary Listing of Intersect ENT.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Intersect ENT is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Intersect ENT's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Intersect ENT has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Intersect ENT expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Intersect ENT expected to grow at an attractive rate?
  • Unable to compare Intersect ENT's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Intersect ENT's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Intersect ENT's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:XENT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:XENT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 7.5%
NasdaqGM:XENT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 14.7%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:XENT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:XENT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 211 1
2023-12-31 179 -39 2
2022-12-31 157 -6 -34 7
2021-12-31 134 -25 -46 7
2020-12-31 112 -47 -58 9
2020-04-08
NasdaqGM:XENT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 109 -27 -43
2019-09-30 110 -25 -40
2019-06-30 111 -23 -35
2019-03-31 110 -17 -28
2018-12-31 108 -14 -23
2018-09-30 105 -11 -21
2018-06-30 103 -9 -18
2018-03-31 101 -6 -16
2017-12-31 96 -8 -16
2017-09-30 91 -10 -18
2017-06-30 87 -13 -20
2017-03-31 82 -18 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Intersect ENT is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Intersect ENT's revenue is expected to grow by 14.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:XENT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Intersect ENT Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:XENT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31 -1.00 -1.00 -1.00 1.00
2022-12-31 -0.97 -0.47 -1.24 6.00
2021-12-31 -1.30 -1.04 -1.57 7.00
2020-12-31 -1.76 -1.61 -2.33 7.00
2020-04-08
NasdaqGM:XENT Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.37
2019-09-30 -1.29
2019-06-30 -1.13
2019-03-31 -0.90
2018-12-31 -0.76
2018-09-30 -0.70
2018-06-30 -0.60
2018-03-31 -0.54
2017-12-31 -0.56
2017-09-30 -0.62
2017-06-30 -0.70
2017-03-31 -0.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Intersect ENT will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Intersect ENT's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Intersect ENT has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Intersect ENT performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Intersect ENT's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Intersect ENT does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Intersect ENT's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Intersect ENT's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Intersect ENT's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Intersect ENT Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:XENT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 109.14 -42.99 108.48 24.28
2019-09-30 110.17 -40.07 107.57 24.20
2019-06-30 110.78 -34.82 103.90 22.92
2019-03-31 110.42 -27.59 97.29 21.26
2018-12-31 108.47 -22.92 91.60 19.26
2018-09-30 105.22 -21.04 87.58 19.14
2018-06-30 102.87 -17.71 83.57 18.61
2018-03-31 100.55 -15.82 81.24 18.41
2017-12-31 96.30 -16.36 80.05 18.36
2017-09-30 91.00 -18.03 77.58 18.31
2017-06-30 87.16 -19.99 76.74 18.20
2017-03-31 82.49 -23.68 75.85 18.62
2016-12-31 78.71 -25.22 72.93 18.89
2016-09-30 72.17 -26.15 69.57 17.77
2016-06-30 67.93 -29.66 68.09 18.33
2016-03-31 63.81 -29.52 64.41 17.78
2015-12-31 61.59 -26.63 59.64 16.61
2015-09-30 55.53 -24.58 54.65 14.78
2015-06-30 50.40 -20.72 47.90 12.74
2015-03-31 43.76 -19.29 42.07 11.08
2014-12-31 37.89 -18.36 36.11 10.33
2014-09-30 31.83 -19.31 30.71 10.48
2014-06-30 27.01 -17.52 25.74 9.80
2014-03-31 22.38 -18.03 21.54 9.84
2013-12-31 17.63 -18.37 18.23 9.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Intersect ENT has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Intersect ENT has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Intersect ENT improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Intersect ENT's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Intersect ENT has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Intersect ENT's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Intersect ENT's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Intersect ENT is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Intersect ENT's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Intersect ENT's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Intersect ENT has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Intersect ENT Company Filings, last reported 3 months ago.

NasdaqGM:XENT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 118.06 0.00 90.64
2019-09-30 110.88 0.00 89.23
2019-06-30 118.07 0.00 93.47
2019-03-31 118.75 0.00 97.59
2018-12-31 120.99 0.00 100.77
2018-09-30 119.81 0.00 104.02
2018-06-30 122.38 0.00 104.90
2018-03-31 118.38 0.00 103.25
2017-12-31 117.22 0.00 102.32
2017-09-30 114.04 0.00 102.50
2017-06-30 113.11 0.00 100.03
2017-03-31 110.16 0.00 98.36
2016-12-31 114.40 0.00 103.95
2016-09-30 116.73 0.00 108.68
2016-06-30 121.08 0.00 111.78
2016-03-31 124.19 0.00 117.01
2015-12-31 130.23 0.00 124.30
2015-09-30 133.57 0.00 131.05
2015-06-30 141.73 0.00 136.50
2015-03-31 49.68 0.00 42.91
2014-12-31 53.81 0.00 48.44
2014-09-30 56.94 0.00 53.62
2014-06-30 6.05 1.11 2.75
2014-03-31 10.48 1.28 7.48
2013-12-31 14.14 1.45 12.29
  • Intersect ENT has no debt.
  • Intersect ENT currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Intersect ENT has sufficient cash runway for 2.9 years based on current free cash flow.
  • Unable to confirm if Intersect ENT has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Intersect ENT's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Intersect ENT has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Intersect ENT's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Intersect ENT dividends. Estimated to be 0% next year.
If you bought $2,000 of Intersect ENT shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Intersect ENT's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Intersect ENT's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:XENT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:XENT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Intersect ENT has not reported any payouts.
  • Unable to verify if Intersect ENT's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Intersect ENT's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Intersect ENT has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Intersect ENT's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Intersect ENT's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Intersect ENT afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Intersect ENT has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Intersect ENT's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tom West
AGE 55
TENURE AS CEO 0.8 years
CEO Bio

Mr. Thomas A. West, also known as Tom, has been President, Chief Executive Officer and Director of Intersect ENT, Inc. since July 22, 2019. Mr. West was Division President of Diagnostics Solutions at Hologic, Inc., since October 2014 until July 1, 2019. From 1992 to 2014, Mr. West worked at Johnson & Johnson in various roles of increasing responsibility across the globe. He served as the Worldwide Vice President of Strategy and Business Development for Johnson & Johnson's Diabetes Solutions Companies. Mr. West served as President of North America at LifeScan, Inc., a division of Johnson & Johnson. Mr. West joined the LifeScan Europe, Middle East and Africa (EMEA) leadership team in January 2003 when he assumed the position of Vice President of Marketing. In 2004, he took on direct responsibility for Italy and the United Kingdom, along with his regional marketing role. Shortly there after, Germany and France were added to his responsibilities. In March 2005, 10 months prior to Mr. West relocating to the United States, he served as the President of LifeScan EMEA. In his 14 years with Johnson & Johnson he has held a broad range of leadership positions covering general management, marketing, international franchise management and business development. Mr. West has worked in consumer products, over-the-counter and prescription pharmaceuticals and diagnostics at LifeScan. He has been a Director of California Healthcare Institute since February 2008. Mr. West holds an Master's of Business Administration in Marketing and Strategic Management from the Wharton School of University of Pennsylvania and a Bachelor’s degree in Politics and Economics from Princeton University.

CEO Compensation
  • Insufficient data for Tom to compare compensation growth.
  • Insufficient data for Tom to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Intersect ENT management team in years:

1.3
Average Tenure
58
Average Age
  • The average tenure for the Intersect ENT management team is less than 2 years, this suggests a new team.
Management Team

Kieran Gallahue

TITLE
Executive Chairman
COMPENSATION
$207K
AGE
56
TENURE
0.8 yrs

Christine Kowalski

TITLE
Executive VP & COO
COMPENSATION
$1M
AGE
61
TENURE
1.5 yrs

David Lehman

TITLE
Executive VP
COMPENSATION
$1M
AGE
58
TENURE
4.2 yrs

Jeri Hilleman

TITLE
COMPENSATION
$2M
AGE
61
TENURE
0.4 yrs

Tom West

TITLE
President
AGE
55
TENURE
0.8 yrs

Randy Meier

TITLE
Executive VP & CFO
AGE
59
TENURE
0.4 yrs

Gwen Carscadden

TITLE
Chief People Officer
COMPENSATION
$439K
AGE
58
TENURE
3.8 yrs

Rob Binney

TITLE
Chief Commercial Officer
COMPENSATION
$375K
AGE
49
TENURE
1.3 yrs

Drake Parker

TITLE
Advisor of Strategic Initiatives
COMPENSATION
$855K
AGE
55
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Intersect ENT board of directors in years:

5
Average Tenure
60
Average Age
  • The tenure for the Intersect ENT board of directors is about average.
Board of Directors

Kieran Gallahue

TITLE
Executive Chairman
COMPENSATION
$207K
AGE
56
TENURE
0.9 yrs

Tom West

TITLE
President
AGE
55
TENURE
0.8 yrs

Dana Mead

TITLE
Independent Director
COMPENSATION
$192K
AGE
60
TENURE
12.8 yrs

Cindy Lucchese

TITLE
Independent Director
COMPENSATION
$193K
AGE
59
TENURE
5.8 yrs

Tony Vernon

TITLE
Independent Director
COMPENSATION
$185K
AGE
63
TENURE
5 yrs

Fred Moll

TITLE
Independent Director
COMPENSATION
$173K
AGE
67
TENURE
14.1 yrs

Terri Kline

TITLE
Independent Director
COMPENSATION
$175K
AGE
60
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Intersect ENT individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
18. Mar 20 Buy Thomas West Individual 17. Mar 20 17. Mar 20 19,035 $8.48 $161,434
17. Mar 20 Buy Richard Meier Individual 17. Mar 20 17. Mar 20 5,000 $7.80 $38,997
17. Mar 20 Buy Richard Meier Individual 16. Mar 20 16. Mar 20 10,000 $13.75 $125,463
07. Nov 19 Sell Robert Binney Individual 05. Nov 19 05. Nov 19 -3,647 $21.54 $-78,555
X
Management checks
We assess Intersect ENT's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Intersect ENT has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Those Who Purchased Intersect ENT (NASDAQ:XENT) Shares A Year Ago Have A 38% Loss To Show For It

(NASDAQ:XENT) have tasted that bitter downside in the last year, as the share price dropped 38%. … See our latest analysis for Intersect ENT Intersect ENT isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Given this lacklustre revenue growth, the share price drop of 38% seems pretty appropriate.

Simply Wall St -

Does Market Volatility Impact Intersect ENT, Inc.'s (NASDAQ:XENT) Share Price?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Given that it has a beta of 0.90, we can surmise that the Intersect ENT share price has not been strongly impacted by broader market volatility (over the last 5 years). … This suggests that including it in your portfolio will reduce volatility arising from broader market movements, assuming your portfolio's weighted average beta is higher than 0.90.

Simply Wall St -

Should You Worry About Intersect ENT, Inc.'s (NASDAQ:XENT) CEO Pay Cheque?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Lisa Earnhardt's Compensation Compare With Similar Sized Companies. … While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$540k.

Simply Wall St -

What Do Analysts Think About Intersect ENT, Inc.'s (NASDAQ:XENT) Future?

(NASDAQ:XENT) released its latest earnings announcement, which … that losses became smaller relative to the prior year's level … - great news for investors

Simply Wall St -

Can You Imagine How Intersect ENT's Shareholders Feel About The 81% Share Price Increase?

Intersect ENT isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Simply Wall St -

Read This Before Selling Intersect ENT, Inc. (NASDAQ:XENT) Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So shareholders might well want to know whether insiders have been buying or selling shares in Intersect ENT, Inc. … It is perfectly legal for company insiders, including board members, to buy and sell stock in a company.

Simply Wall St -

What Did Intersect ENT Inc's (NASDAQ:XENT) CEO Take Home Last Year?

How Does Lisa Earnhardt's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Intersect ENT Inc has a market cap of US$922m, and is paying total annual CEO compensation of US$3.3m. … We examined companies with market caps from US$400m to US$1.6b, and discovered that the median CEO compensation of that group was US$2.2m.

Simply Wall St -

Is Intersect ENT Inc's (NASDAQ:XENT) Balance Sheet A Threat To Its Future?

Intersect ENT Inc (NASDAQ:XENT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Zero-debt can alleviate some risk associated with the company meeting debt obligations, but this doesn’t automatically mean XENT has outstanding financial strength. … Is financial flexibility worth the lower cost of capital.

Simply Wall St -

How Confident Are Insiders About Intersect ENT Inc (NASDAQ:XENT)?

Intersect ENT's insiders have divested from. … A well-known argument is that insiders divesting from their own companies’ shares sends a pessimistic signal … The MIT Press (1998) published an article showing that stocks following insider selling underperformed the market by 2.7%

Simply Wall St -

Intersect ENT Inc's (NASDAQ:XENT) Profit Outlook

Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. … With the latest financial year loss of -US$16.36m and a trailing-twelve month of -US$15.82m, the US$1.09b market-cap alleviates its loss by moving closer towards its target of breakeven. … Many investors are wondering the rate at which XENT will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Company Info

Description

Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

Details
Name: Intersect ENT, Inc.
XENT
Exchange: NasdaqGM
Founded: 2003
$307,474,884
32,297,782
Website: http://www.intersectent.com
Address: Intersect ENT, Inc.
1555 Adams Drive,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM XENT Common Stock Nasdaq Global Market US USD 24. Jul 2014
DB 7IN Common Stock Deutsche Boerse AG DE EUR 24. Jul 2014
Number of employees
Current staff
Staff numbers
402
Intersect ENT employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 08:21
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.